FENNEC PHARMACEUTICALS INC (FENC)
Health Care · Specialty pharmaceuticals / oncology support therapy · NASDAQ
Commercial-stage biopharma company bringing PEDMARK, the first and only approved drug to prevent cisplatin-induced ototoxicity in pediatric cancer patients, to market.
What FENNEC PHARMACEUTICALS INC does
Fennec Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing PEDMARK, a product for treating ototoxicity (hearing damage) caused by chemotherapy. The company has received FDA and European Commission marketing approvals for PEDMARK and is actively commercializing the product in the US and Europe. Fennec operates as a single-product company with a network of third-party manufacturing, clinical, and commercial partners globally.
Themes: ["ototoxicity / hearing preservation"]
Fundamentals
- Price$10.31 as of 2026-07-09 close
- Market cap$358M as of 2026-07-10
- 1-year return+16.0% as of 2026-07-09 close
- Net margin-12.6% as of 2026-07-10
- Gross margin+92.8% as of 2026-07-10
- ROE-12.5% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Revenue growth (YoY)+33.8% as of 2026-07-10
- Revenue CAGR (3y)+207.5% SEC XBRL
- Beta1.06 as of 2026-07-10
Key risks (from latest filing)
["Single-product company with limited revenue history and negative net margins; commercial success entirely dependent on PEDMARK uptake and reimbursement in US and Europe"]
Competitors & peers
- Apeiron Therapeutics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.